Inhibitory effect of 2'-O-benzoylcinnamaldehyde on vascular endothelial cell proliferation and migration.
OBJECTIVE
To evaluate the inhibitory effect of the farnesyl transferase inhibitor 2'-O-benzoylcinnamaldehyde (CB 2'-ph) on proliferation and migration of vascular endothelial cells.


METHODS
Bovine lens epithelial cells, bovine corneal endothelial cells, bovine keratocytes, bovine aortic endothelial cells (BAECs) and human umbilical vein endothelial cells (HUVECs) were treated with CB 2'-ph to determine its cell type specificity and antiproliferative effect. For inhibition of vascular endothelial cell growth factor (VEGF)- or basic fibroblast growth factor (bFGF)-induced proliferation of HUVECs, these cells were treated with various concentrations of CB 2'-ph. To assess the proliferation, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assay was used. The migration assay was also performed to determine the effect of CB 2'-ph on HUVECs. The distance of HUVEC outgrowth was measured from the scraped edge of a monolayer after treatment with CB 2'-ph concentrations of 0, 1.5 and 2.5 microg/ml for 24, 48 and 72 h.


RESULTS
The CB 2'-ph had an inhibitory effect on all tested types of cell proliferation but only HUVEC and BAEC proliferation was specifically inhibited in a dose-dependent manner. In addition, CB 2'-ph inhibited VEGF- or bFGF-induced proliferation and migration of HUVECs in a dose-dependent manner.


CONCLUSIONS
These results indicate that CB 2'-ph, a farnesyl transferase inhibitor is thought to be an effective inhibitor of vascular endothelial cell proliferation and migration.
Department of Ophthalmology and Visual Science, Catholic Research Institute of Medical Science, The Catholic University of Korea, College of Medicine, Seoul, Korea.
J Y
JY
Park
B M
BM
Kwon
S K
SK
Chung
J H
JH
Kim
C K
CK
Joo
D000171:Acrolein / Q000031:analogs & derivatives / Q000494:pharmacology*; D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors*; D000818:Animals; D002417:Cattle; D002455:Cell Division / Q000187:drug effects*; D002465:Cell Movement / Q000187:drug effects*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D016228:Endothelial Growth Factors / Q000494:pharmacology; D004728:Endothelium, Corneal / Q000166:cytology / Q000187:drug effects; D004730:Endothelium, Vascular / Q000166:cytology* / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004847:Epithelial Cells; D051231:Farnesyltranstransferase; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D007908:Lens, Crystalline / Q000166:cytology; D008222:Lymphokines / Q000494:pharmacology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
C426784:2'-O-benzoylcinnamaldehyde; D016228:Endothelial Growth Factors; D004791:Enzyme Inhibitors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D000171:Acrolein; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase